NuVasive expanded its orthobiologic portfolio with U.S. launch of traditional bone allograft, Amniotic Membrane DS and additional form factors for the Propel™ DBM product line.
Allograft is available as cancellous chips, demineralized cancellous chips, cortical cancellous chips and cancellous crushed in a range of grind sizes and volumes.
Double-sided human Amniotic Membrane DS is intended to address adhesion prevention and scar tissue formation. Due to its natural growth factor content, it has been shown to control inflammation and reduce bacterial and viral activity at the surgical site.
Propel DBM now includes gel, gel plus and putty plus as additional form factors to address surgeon preference. Gel is delivered in a syringe, and putty plus and gel plus contain cancellous chips for additional osteoconductive properties. The Propel line also includes fibers.
These products, as well as U.S. launch of AttraX® Scaffold in 2Q18, will support 2H18 improvements to NUVA's orthobiologic revenue. ORTHOWORLD estimates that the company's 1H18 orthobiologic revenue was $54.0MM, -8.3% vs. 1H17.
Sources: NuVasive, Inc.; ORTHOWORLD Inc.